Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

April 30, 2026 · TopStocks

PONTE VEDRA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today announced a major regulatory milestone after successfully completing its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) and receiving guidance on key elements of the Phase 3 pivotal trial for CAD-1005, the Company’s investigational first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT).

The FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT. Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy.

The meeting with the FDA provided guidance on protocol design, study population, dosing, background therapy, exposure, the safety database, and the primary endpoint of new or worsening thrombotic events. After considering FDA feedback on a pivotal registration study, Cadrenal plans to advance directly to a randomized, blinded, placebo-controlled Phase 3 study evaluating CAD-1005 added to the current standard of care for patients with HIT.

“This successful EOP2 meeting marks an important regulatory milestone for Cadrenal and our CAD-1005 program,” said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. “Building on our Phase 2 experience with CAD-1005 in HIT and now with FDA guidance for Phase 3, Cadrenal is positioned to pursue a pivotal trial for the first new therapy for HIT in more than two decades.”

Planned Phase 3 HIT Trial Design

Cadrenal’s planned pivotal Phase 3 study — the first randomized, blinded, placebo-controlled registration trial in HIT — will evaluate CAD-1005 in approximately 120 patients across up to 50 clinical centers worldwide and is intended to support a projected NDA submission in 2029.

Patients with suspected HIT will be randomized to CAD-1005 or placebo while receiving standard-of-care anticoagulant therapy and treated for up to 14 days during hospitalization. The primary endpoint, which will be centrally adjudicated, is the incidence of new or worsening thrombotic events in patients with Serotonin Release Assay (SRA)-confirmed HIT, with at least one planned interim analysis.

“CAD-1005 is being investigated for the treatment of immune-mediated thrombocytopenia by targeting the underlying pathophysiologic mechanisms that current therapies do not,” said James Ferguson, M.D., Chief Medical Officer of Cadrenal Therapeutics. “Interrupting the vicious cycle of platelet activation in HIT with CAD-1005 could be an important addition to our therapeutic armamentarium for this devastating condition.”

About Heparin-Induced Thrombocytopenia (HIT)

Heparin is the most widely used in-hospital anticoagulant, with more than 12 million patients receiving it in the United States each year. Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening immune-mediated complication of heparin administration that occurs when antibodies to heparin activate platelets, leading to clots throughout the circulatory system, markedly lowering platelet counts, and increasing the risk of bleeding.

Complications of HIT include deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, amputation, and death, with mortality rates for HIT exceeding 20% in some studies. CAD-1005 is the only treatment in clinical development that targets the underlying immune drivers of HIT.

About CAD-1005

CAD-1005 is an investigational therapy under evaluation for the treatment of suspected HIT. CAD-1005 is designed to selectively inhibit 12-LOX, a pathway integral to the primary immune mechanisms that drive HIT.

Unlike existing therapies for HIT, which are directed only at preventing thrombotic complications, this approach targets the primary underlying cause of HIT. CAD-1005 has received Orphan Drug Designation (ODD) and Fast Track designation from the U.S. Food and Drug Administration, as well as orphan drug status from the European Medicines Agency.

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its lead program, CAD-1005, is a first-in-class 12-LOX inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration and orphan drug status from the European Medicines Agency. Second-generation 12-LOX oral therapeutics are also in development for chronic indications.

The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease and left ventricular assist devices, and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings.

For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.

Safe Harbor

Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These statements include, without limitation, statements regarding Cadrenal’s plans to advance to a pivotal Phase 3 in HIT; plans to advance directly to a randomized, blinded, placebo-controlled Phase 3 study evaluating CAD-1005 added to the current standard of care for patients with HIT; Cadrenal being positioned to pursue a pivotal trial for the first new therapy for HIT in more than two decades; the planned pivotal Phase 3 study evaluating CAD-1005 in approximately 120 patients across up to 50 clinical centers worldwide and being intended to support a projected NDA submission in 2029; the protocol design including patients with suspected HIT being randomized to CAD-1005 or placebo while receiving standard-of-care anticoagulant therapy and treated for up to 14 days during hospitalization with the primary endpoint, centrally adjudicated, being the incidence of new or worsening thrombotic events in patients with Serotonin Release Assay (SRA)-confirmed HIT, with at least one planned interim analysis; and interrupting the vicious cycle of platelet activation in HIT with CAD-1005 being an important addition to our therapeutic armamentarium for this devastating condition.

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to continue to progress CAD-1005; the ability to successfully plan a pivotal Phase 3 study; the ability to successfully plan and conduct a randomized, blinded, placebo-controlled Phase 3 study evaluating CAD-1005 added to the current standard of care for patients with HIT; the ability of the Company’s planned Phase 3 pivotal trial to support a projected NDA in 2029; the ability to interrupt the vicious cycle of platelet activation in HIT with CAD-1005; the Company’s ability to raise sufficient funding to commence and complete its planned Phase 3 trial, and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information, please contact:

Lytham Partners, LLC

Robert Blum, Managing Partner

602-889-9700

CVKD@lythampartners.com

MASTER LEGAL DISCLAIMER

Last Updated: Apr 30, 2026

Publisher: Relqo Media LLC (Wyoming, United States)

Subject Company: Cadrenal Therapeutics, Inc. (CVKD)

IMPORTANT SUMMARY — PLEASE READ FIRST

This website and any affiliated digital materials are published by Relqo Media LLC, a Wyoming marketing agency that has been compensated in cash by Penzance LLC to produce and distribute promotional content regarding Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). This communication is a paid advertisement, not a research report, not investment advice, and not an independent publication. Relqo Media is not a broker-dealer, investment adviser, or securities analyst. Investing in small-cap or microcap securities is extremely speculative and may result in the total loss of your investment. We strongly urge all viewers to consult a licensed investment professional and perform their own due diligence.

1. NATURE AND INTENT OF THIS COMMUNICATION

Relqo Media LLC is a for-profit marketing agency engaged in paid promotions of public companies. The content we produce is strictly commercial and intended to create temporary public awareness, visibility, and short-term market activity around the featured company. This material is not impartial. All readers should interpret our content as a paid commercial advertisement and not as an editorial, research article, or independent commentary. We create advertisements, not analysis. These Communications are not intended to be factual evaluations of the company’s operations or investment merit.

2. COMPENSATION FOR CADRENAL THERAPEUTICS, INC. (CVKD)

Relqo Media LLC ("Relqo Media") has been engaged by Penzance LLC to provide promotional media and digital investor awareness services with respect to Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). The following details outline the nature, scope, and financial terms of this engagement:

Relqo Media received cash compensation of $25,000 for a 5 day campaign covering April 27th , 2026, through May 1st 2026.
Relqo Media received cash compensation of $25,000 for a 5 day campaign covering March 9th , 2026, through March 13th 2026.
Relqo Media received cash compensation of $25,000 for a 4 day campaign covering March 1st , 2026, through March 5th 2026.
Relqo Media received cash compensation of $25,000 for a 5 day campaign covering February 23rd , 2026, through february 28th 2026.
Relqo Media received cash compensation of $25,000 for a 5 day campaign covering February 18th , 2026, through february 23rd 2026.
Relqo Media received cash compensation of $25,000 for a 6 day campaign covering January 25th , 2026, through January 30th 2026.
Relqo Media received cash compensation of $25,000 for a 7 day campaign covering January 12, 2026, through January 19, 2026.
Relqo Media received cash compensation of $25,000 for a campaign covering December 10, 2025, through December 17, 2025.
Relqo Media received cash compensation of $25,000 for a campaign covering December 2, 2025, through December 10, 2025.
Relqo Media continued to receive cash compensation on a week to week basis at a rate of $25,000 per week, paid weekly, from July 26, 2025, through September 9, 2025, resulting in aggregate additional compensation of $150,000.
Relqo Media received additional cash compensation at the same weekly rate of $25,000 per week, paid weekly, covering the period from June 26, 2025, through July 26, 2025, resulting in aggregate compensation of $100,000.
Relqo Media received cash compensation from Penzance LLC for digital investor awareness and promotional services at a rate of $25,000 per week, paid weekly, beginning January 1, 2025, through July 1, 2025, resulting in aggregate compensation of $650,000 during that period.
Total Compensation: As of January 19, 2026, Relqo Media has received cumulative cash compensation of $975,000 from Penzance LLC for services rendered in connection with CVKD.
Future Compensation: This engagement continues on an open ended basis at a rate of $25,000 per week, paid weekly, until terminated by either party. Accordingly, Relqo Media will continue to receive compensation at this rate beyond January 19, 2026, unless and until such agreement is terminated or modified in writing.
Nature of Services: Relqo Media's services include, but are not limited to, creating, publishing, and distributing digital media, promotional articles, newsletters, websites, investor awareness content, social media campaigns, email/SMS marketing, and other investor-focused communications designed to raise awareness of CVKD among retail and institutional investors.
Conflict of Interest Statement: Because Relqo Media has been, and will continue to be, compensated directly by Penzance LLC for its services, this relationship represents a material conflict of interest. Relqo Media's communications regarding CVKD, including but not limited to newsletters, articles, press releases, advertisements, websites, emails, SMS alerts, and social media posts, should be understood as paid advertisements that are inherently biased.
Securities Ownership Disclosure: Penzance LLC and/or its affiliates, officers, directors, or associated individuals may own, acquire, or dispose of securities of Cadrenal Therapeutics, Inc. before, during, or after the campaign period. This means that while Relqo Media is being compensated to promote CVKD, the entities paying for such services may simultaneously engage in securities transactions involving CVKD stock, which could result in gains or losses to those parties independent of Relqo Media's activities.
Investor Warning: All readers, investors, and market participants should assume that any and all promotional communications disseminated by Relqo Media regarding CVKD are issued for the purpose of increasing investor awareness and may have the effect of increasing trading volume and/or the market price of CVKD's securities. Investors are strongly cautioned to conduct their own independent research, due diligence, and analysis of CVKD, including review of all filings made with the Securities and Exchange Commission (SEC), prior to making any investment decision.

This relationship creates a material conflict of interest. All content distributed by Relqo Media LLC regarding CVKD should be viewed as promotional, financially motivated, and inherently biased.

3. INTENDED AUDIENCE

These Communications are directed solely to U.S.-based, self-directed investors who understand the risks of investing in microcap and Nasdaq-listed securities. The content is not intended for children, seniors, retirement accounts, or individuals with limited experience in securities trading. These Communications are not intended to guide investment for long-term portfolio management or financial planning purposes.

4. NO ENDORSEMENT OR VERIFICATION OF COMPANY CLAIMS

Relqo Media LLC does not, and has not, independently verified, investigated, audited, or substantiated any statements, representations, or claims made by the featured company, its officers, directors, employees, affiliates, agents, press releases, marketing materials, or any third-party sources.

Any and all information regarding Cadrenal Therapeutics, Inc. (NASDAQ: CVKD)—including but not limited to business descriptions, operational updates, clinical trial progress, scientific data, partnerships, revenue projections, market opportunity estimates, or strategic plans—should be assumed to be unverified, unaudited, incomplete, potentially inaccurate, and subject to change without notice.

We make no warranties or representations as to the truthfulness, accuracy, reliability, or completeness of such information, and you should not interpret our publication of these statements as an endorsement or confirmation of their validity.

You should not rely on any company-provided claims, projections, or forward-looking statements for the purpose of making an investment decision. All such statements may be speculative, overstated, selectively presented, or based on assumptions that may never materialize.

If you choose to invest, you do so entirely at your own risk, and you should conduct thorough, independent due diligence—including reviewing SEC filings, consulting licensed investment professionals, and obtaining independent verification of any material facts—before making any investment decision.

5. MARKET INFLUENCE AND TRADING PATTERN EXPECTATION

Historically, promotional campaigns for microcap and small-cap securities—particularly those driven by paid advertising—often cause temporary, artificial, and unsustainable increases in share price and trading volume. These movements are typically fueled by short-term speculative interest, promotional circulation, algorithmic trading activity, and momentum-based retail buying rather than any change in the underlying business, operations, or financial condition of the company.

You should assume and expect that:

CVKD’s share price may experience sharp, rapid, and potentially extreme increases during the period of active promotion;
Trading volume may spike dramatically due to speculative buying pressure, news catalysts amplified by promotional activity, and social media or online forum chatter;
Once buying interest subsides, selling begins, or the promotion ends—which may occur suddenly and without notice—the share price may decline precipitously, potentially returning to pre-promotion levels or lower, often within days or even hours; and
These price and volume movements are not reflective of intrinsic value and may have no correlation to the company’s actual fundamentals or long-term business prospects.

Past market behavior shows that such promotional price spikes are frequently followed by steep losses, which can be rapid and irreversible. If you purchase shares during or shortly after a promotional period, you should be prepared for the high probability of losing a substantial portion, or all, of your investment.

By engaging with our content, you acknowledge and agree that you fully understand the speculative, volatile, and high-risk nature of securities subject to promotional activity, and you will not hold Relqo Media LLC responsible for any losses resulting from such trading patterns.

6. NO RELIANCE – INVESTOR RESPONSIBILITY

The burden of research, verification, and risk assessment rests entirely with you, the reader. All content produced and distributed by Relqo Media LLC is promotional in nature and should not be the basis for any investment decision. We are not responsible for your interpretation or use of the information contained herein.

You are solely responsible for:

Reviewing and analyzing all publicly available information, including but not limited to SEC filings, audited financial statements, and official company disclosures;
Consulting with a licensed, qualified investment professional, attorney, or tax adviser before making any investment decision;
Understanding and accepting the risks inherent in microcap and early-stage public companies, which may include extreme volatility, illiquidity, lack of financial transparency, insider selling, share dilution, regulatory challenges, and business failure.

We make no warranties or representations as to the accuracy, completeness, timeliness, or reliability of any information presented. Any data, figures, or statements regarding the featured company’s business, market opportunity, future performance, or partnerships may be incomplete, outdated, or incorrect. You should assume that certain information is based on third-party sources we have not independently verified.

By viewing our materials, you agree that:

You will not rely solely on our communications in making an investment decision;
You accept full responsibility for conducting independent due diligence; and
Relqo Media LLC and its affiliates will not be liable for any losses or damages arising from your reliance on our content.

7. FORWARD-LOOKING STATEMENTS, ASSUMPTIONS, AND ACCURACY NOTICE

Our materials may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as well as other predictive or aspirational language regarding future events, performance, or results. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “may,” “will,” “should,” “could,” “projects,” “estimates,” “potential,” and similar expressions are intended to identify such statements. These statements are inherently uncertain, based on current expectations, estimates, and assumptions that may prove to be incorrect, incomplete, or no longer applicable at the time you read them.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to: changes in market conditions, regulatory decisions, the outcome of clinical trials, competitive pressures, the availability of financing, and broader economic or geopolitical developments.

Additionally, some information presented in our content is derived from third-party sources, company press releases, or statements from officers, directors, or affiliates of the featured company. We do not independently verify or guarantee the accuracy, completeness, or timeliness of such information. Any claim, projection, or forward-looking statement should be considered purely speculative and potentially outdated..

You should not place undue reliance on forward-looking statements or assume that they will prove to be accurate. Relqo Media LLC undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events, changes in circumstances, or the emergence of new information, except as required by law.

8. INFORMATION SOURCING, BIAS, AND ACCURACY

We use publicly available information including company websites, press releases, and promotional materials supplied by paying clients or related parties. We do not verify or validate this data.

Assume all information presented by Relqo Media is:

Subjective,
Not independently verified,
Created to highlight potential upside and omit downsides,
Not suitable as the basis for any investment decision.

9. OWNERSHIP AND TRADING CONFLICTS

Relqo Media LLC, its contractors, members, and affiliates may hold or acquire shares in the companies we promote, including CVKD. We may buy or sell such shares without prior notice. These transactions may occur before, during, or after a promotional campaign and may affect market pricing. We are not obligated to update readers on our trading activity or affiliate holdings.

10. MARKETING TOOLS, DATA COLLECTION, AND USER CONSENT

We use a range of outreach and promotional tools, including:

Email and newsletter distributions,
SMS/MMS text campaigns,
Social media posts and influencers,
Google and native display ads,
Press releases, video marketing, and paid content distribution.

By engaging with our content, you consent to receive ongoing marketing communications. You may unsubscribe, but your data may be retained for audit or compliance purposes. Please refer to our Privacy Policy for further details.

11. ADVERTISING LAW COMPLIANCE

Relqo Media LLC produces promotional content in accordance with the advertising disclosure standards set forth by the Federal Trade Commission (FTC) and the SEC’s interpretations of sponsored investment-related communications.

We make good-faith efforts to disclose all:

Compensation arrangements,
Conflicts of interest,
Risks,
Limitations of our role, and
The promotional nature of this content.

We do not provide investment recommendations under any regulatory framework including, but not limited to, SEC Regulation Analyst Certification, FINRA Rule 2210, or Regulation Best Interest.

12. NON-U.S. USERS

This material is intended solely for distribution within the United States. If you are accessing this site from outside the U.S., you are responsible for complying with your country’s laws. Relqo Media disclaims liability for access from non-U.S. jurisdictions where investor promotion, marketing, or solicitation of securities is restricted or prohibited.

13. DISCLAIMER OF WARRANTIES AND LIMITATION OF LIABILITY

All content is provided “as-is” and without warranties of any kind, either express or implied. Relqo Media LLC disclaims any and all liability for:

Investment losses,
Inaccuracies,
Technical delays,
User misunderstandings,
Omissions or errors in content.

Total liability for any claim shall not exceed one hundred dollars ($100).

14. LEGAL GOVERNANCE AND DISPUTE RESOLUTION

All matters arising out of this disclaimer shall be governed by the laws of the State of Wyoming. You agree that any dispute shall be resolved exclusively through binding arbitration under the rules of the American Arbitration Association, to be held in Sheridan County, Wyoming. Class action claims and group arbitration are expressly prohibited.

15. NON-SOLICITATION AND GEOGRAPHIC LIMITATIONS

Nothing in our content constitutes a general solicitation or a personal securities recommendation. If you reside in a jurisdiction where such communications are unlawful, you must exit this site and discontinue engagement with our content.

16. FINAL NOTICE – ACCEPTANCE OF TERMS

We reserve the right to update this Disclaimer at any time without notice. Your continued use of our services or content constitutes acceptance of the most recent version.

If you do not accept all terms of this disclaimer in full, you must:

Exit our websites,
Unsubscribe from our communications,
Discontinue viewing all Relqo Media promotional content.

17. NO RELIANCE

By viewing or engaging with this content, you agree that:

You will not rely on any statements made by Relqo Media for investment purposes,
You waive any claim that our content was a material factor in your investment decision,
You have read, understood, and accepted this disclaimer in full.

Legal Contact: 📧 support@topstocks.com

Mailing Address: 1309 Coffeen Ave Ste 1200, Sheridan, WY 82801

Affiliate Disclosure: Relqo Media LLC owns and operates TopStocks.com and all affiliated digital properties.